We are live on ! Find out more
CRDF icon

Cardiff Oncology
CRDF

67 hedge funds and large institutions have $264M invested in Cardiff Oncology in 2020 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

971% more capital invested

Capital invested by funds: $24.7M → $264M (+$240M)

760% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 5

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

131% more funds holding

Funds holding: 29 → 67 (+38)

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

50.19% more ownership

Funds ownership: 24.66% → 74.84% (+50%)

4% less call options, than puts

Call options by funds: $8.46M | Put options by funds: $8.85M

Holders
67
Holders Change
+38
Holders Change %
+131.03%
% of All Funds
1.35%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.1%
New
43
Increased
12
Reduced
6
Closed
5
Calls
$8.46M
Puts
$8.85M
Net Calls
-$384K
Net Calls Change
-$384K

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$21.7M
2
VA
VR Adviser
New York
+$8.4M
3
OM
Opaleye Management
Massachusetts
+$7.54M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$6.69M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.47M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$5.01M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.35M
3
ACP
Acuta Capital Partners
California
-$671K
4
PFS
Prospera Financial Services
Texas
-$483K
5
XSC
X-Square Capital
Puerto Rico
-$85K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity International
51
Fidelity International
Bermuda
$62K +$29.1K +4,400 New
UBS Group
52
UBS Group
Switzerland
$53K -$4.91K -743 -16%
Osaic Holdings
53
Osaic Holdings
Arizona
$50K +$23.1K +3,500 New
TRCT
54
Tower Research Capital (TRC)
New York
$50K +$23.2K +3,510 New
Royal Bank of Canada
55
Royal Bank of Canada
Ontario, Canada
$28K +$13.2K +2,000 New
DWA
56
Dorsey Wright & Associates
California
$24K +$11.2K +1,701 New
EP
57
Elkhorn Partners
Nebraska
$14K -$43.3K -6,562 -87%
CAPTRUST Financial Advisors
58
CAPTRUST Financial Advisors
North Carolina
$9K – – –
Wells Fargo
59
Wells Fargo
California
$8K +$2.96K +448 +649%
LC
60
Lindbrook Capital
California
$7K +$3.3K +500 New
SFS
61
Sowell Financial Services
Arkansas
$3K -$5.28K -800 -80%
Millennium Management
62
Millennium Management
New York
$1.33K +$620K +93,953 New
Northwestern Mutual Wealth Management
63
Northwestern Mutual Wealth Management
Wisconsin
$1K – – –
GEA
64
Glen Eagle Advisors
New Jersey
$71 – – –
ACA
65
Avoro Capital Advisors
New York
– -$5.01M -1,000,000 Closed
Renaissance Technologies
66
Renaissance Technologies
New York
– -$1.35M -268,800 Closed
PFS
67
Prospera Financial Services
Texas
– -$483K -96,400 Closed
XSC
68
X-Square Capital
Puerto Rico
– -$85K -17,000 Closed
Citigroup
69
Citigroup
New York
– +$79 +12 New
1 2
3

CRDF Hedge Fund Activity: Q3 2020 in Review

67 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q3 2020, worth a combined $264M — up 971% from $24.7M a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new CRDF positions and 5 closed out — a net gain of 38 holders — while 12 added to existing stakes and 6 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $21.7M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $5.01M sold.

  • 67 institutional investors held Cardiff Oncology (CRDF) as of Q3 2020, up from 29 in Q2 2020.
  • Funds reported $264M of Cardiff Oncology stock for Q3 2020, up 971% quarter-over-quarter.
  • 43 funds opened new Cardiff Oncology positions in Q3 2020 and 5 closed out, a net change of +38 holders.
  • The largest Cardiff Oncology buyer in Q3 2020 was RA Capital Management, an estimated $21.7M added.
  • The largest Cardiff Oncology seller in Q3 2020 was Avoro Capital Advisors, an estimated $5.01M sold.

Based on aggregated 13F filings for Q3 2020.